Short-Term Application of Tocilizumab Following Myocardial Infarction

Trial Profile

Short-Term Application of Tocilizumab Following Myocardial Infarction

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions
  • Acronyms STAT-MI
  • Most Recent Events

    • 22 Oct 2017 Status changed from recruiting to completed.
    • 29 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
    • 29 Aug 2016 Planned primary completion date changed from 1 May 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top